US Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Orencia (abatacept) for the Prevention of Acute Graft Versus Host Disease (aGvHD)

Bristol Myers Squibb announced that the FDA has accepted its supplemental Biologics License Application for Orencia for the prevention of moderate to severe aGvHD in patients six years of age and older receiving unrelated donor hematopoietic stem cell transplantation.